Kalen Lumsden is a JD candidate at Osgoode Hall Law School. On June 1, 2011, Pfizer, manufacturer of the erectile dysfunction drug Viagra, filed suit against rival Watson Pharmaceuticals to frustrate its attempts to produce a generic version of the drug. The next day Watson confirmed that it had applied to the US Food and […]
Dan Whalen is a JD candidate at Osgoode Hall Law School. The Canada Gazette published amendments to the Patented Medicines (Notice of Compliance) Regulations, which include much-anticipated provisions for Extraordinary Use New Drugs (EUNDS). This addition is aimed at empowering Canada to prevent and respond to the threat of disease outbreaks and align its approach […]
Dan Whalen is a JD candidate at Osgoode Hall Law School. Among the nearly 500 bills that died with the end of the 40th Canadian Parliament last Friday was Bill C-393, Canada’s Act to amend the Patent Act. The bill proposes to modify Canada’s Access to Medicines Regime (CAMR), itself an amendment to the Patent […]
Dan Whalen is a JD Candidate at Osgoode Hall Law School. The Indian Patent Office recently denied exclusive rights to Abbott Laboratories for a premier HIV-fighting drug – effectively opening up the market to lower-cost generic substitutes. The company’s application was officially contested by four opponents led by the non-governmental organization Initiative for Medicines, Access […]